Briacell Therapeutics Corp (BCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 07/31
| 07-2023 | 04-2023 | 01-2023 | 10-2022 | 07-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,302 | -17,884 | -12,988 | -1,107 | -26,839 |
| Depreciation Amortization | 15 | 12 | 8 | 4 | 15 |
| Accounts receivable | 5 | 9 | 15 | -6 | -12 |
| Accounts payable and accrued liabilities | 661 | 532 | 119 | 329 | 249 |
| Other Working Capital | -3,532 | 414 | 596 | 566 | -391 |
| Other Operating Activity | -592 | 4,091 | 4,756 | -3,329 | 14,493 |
| Operating Cash Flow | $-23,745 | $-12,826 | $-7,494 | $-3,542 | $-12,484 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,002 | 2 | N/A | N/A | 6,510 |
| Common Stock Repurchased | -47 | -47 | -47 | -47 | -10,172 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -81 |
| Financing Cash Flow | $3,954 | $-46 | $-47 | $-47 | $-3,743 |
| Beginning Cash Position | 41,042 | 41,042 | 41,042 | 41,042 | 57,269 |
| End Cash Position | 21,251 | 28,170 | 33,500 | 37,452 | 41,042 |
| Net Cash Flow | $-19,791 | $-12,872 | $-7,541 | $-3,590 | $-16,227 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,745 | -12,826 | -7,494 | -3,542 | -12,484 |
| Free Cash Flow | -23,745 | -12,826 | -7,494 | -3,542 | -12,484 |